ERBB2 and central nervous system neoplasm: Anti-GD2-directed CAR-T cell application for DMG may be another future option, and local delivery of HER2-directed CAR-T cells is currently being tested in children with refractory/relapsed CNS tumors (BrainChild-01, NCT0350099) [15, 47].